Company Long-Term Loans and Borrowings: Biomea (BMEA)

Public company logo of Biomea (BMEA)

The Biomea Fusion, Inc. (BMEA) price chart on the GURU.Markets platform shows figures at 0.00. The company's business is resilient to economic cycles, as drug development depends on testing phases rather than GDP. Optimized cold chains and reliable carriers ensure seamless supplies. The team consists of top scientists who receive substantial bonuses for developing life-saving therapeutics.

BMEA Biomea Fusion, Inc. Company Long-Term Debts (07/04/2022 - 10/30/2026)

Summary analytical data breakdowns for Biomea (BMEA)

- market price and analyst price targets:
Stock Price biomeafusion.com|BMEA - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Biomea Fusion|BMEA - Total Company Value
- book capitalization information:
Accounting Value per Share Biomea Fusion|BMEA - Book Capitalization|Market Capitalization to Book Value Ratio biomeafusion.com|BMEA - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Biomea Fusion Corp|BMEA - Company Aggregate Debts|Debts to Book Value Biomea Fusion|BMEA - Company Long-Term Liabilities|Amount of Current Liabilities Biomea Fusion|Quick Ratio biomeafusion.com
- earnings and multiples data:
BMEA - Net Profit
Summary company analytics:Biomea Fusion, Inc.
Brand item of Biomea Fusion, Inc.

Biomea Fusion, Inc. (BMEA) invests in a highly qualified staff of scientists to develop innovative drugs for cancer and metabolic pathologies. This assessment of the corporation's long-term loans and borrowings on GURU.Markets reflects obligations with maturities exceeding one year. Daily recalculation of the metric eliminates quarterly reporting lags, allowing for precise tracking of debt load dynamics. An optimal leverage balance ensures financial stability and protection against default without suppressing profit growth rates.

Competitor analysis for Biomea Fusion, Inc.

Company Long-Term Debts ascendispharma.com ASND|MDGL - Company Long-Term Debt|Company Long-Term Loans and Borrowings CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Company Long-Term Debt|Company Long-Term Liabilities Akero Corp|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com|Company Long-Term Liabilities CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Soleno SLNO|FOLD - Company Long-Term Liabilities|89bio, Inc. - Company Long-Term Debts|Long-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Long-Term Liabilities|MDXG: Amount of Long-Term Liabilities|RZLT (Rezolute Corp) - Company Long-Term Debts|Company Long-Term Debts Lexicon Corp|Company Long-Term Debts MBX|Company Long-Term Debt ALT (altimmune.com)|Company Long-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Long-Term Debt|BIOA - Company Long-Term Debt|QNCX: Company Long-Term Debt|GUTS: Company Long-Term Debts|VTVT - Long-Term Debt Volume|Company Long-Term Debt Agape ATP Corp|Pluri Inc (PLUR) - Long-Term Debt Volume|Company Long-Term Debt Synlogic, Inc. (SYBX)|Company Long-Term Liabilities Lipocine Corporation LPCN|Company Long-Term Debts MTNB (Matinas BioPharma Holdings)|Spruce Biosciences Inc. - Company Long-Term Debt|Galecto - Company Long-Term Debts|Long-Term Debt Volume Carmell Corp. CTCX|Lumos Pharma Corp (LUMO) - Company Long-Term Debt|Long-Term Debt Organovo Corp (ONVO)|Company Long-Term Debt Radius Recycling, Inc.